Iron Sucrose (2 brand names, 1 dosage form, 1 route)
Available dosage forms: INJECTABLE.
Routes of administration: INTRAVENOUS.
Brand Names
- IRON SUCROSE
- VENOFER
Related Health Topics
Indications and Usage
Iron Sucrose Injection is indicated for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD).
Contraindications
Known hypersensitivity to Iron Sucrose Injection
Adverse Reactions
The following clinically significant adverse reactions are described elsewhere in the labeling:• Hypersensitivity Reactions [ see Warnings and Precautions (5.1) ] • Hypotension [ see Warnings and Precautions (5.2) ] • Iron Overload [ see Warnings and Precautions (5.3) ]
Drug Interactions
Iron Sucrose Injection may reduce the absorption of concomitantly administered oral iron preparations.
Mechanism of Action
Iron Sucrose Injection is an aqueous complex of poly-nuclear iron (III)-hydroxide in sucrose. Following intravenous administration, Iron Sucrose Injection is dissociated into iron and sucrose and the iron is transported as a complex with transferrin to target cells including erythroid precursor cells. The iron in the precursor cells is incorporated into hemoglobin as the cells mature into red blood cells.
Overdosage
No data are available regarding overdosage of Iron Sucrose Injection in humans. Excessive dosages of Iron Sucrose Injection may lead to accumulation of iron in storage sites potentially leading to hemosiderosis. Do not administer Iron Sucrose Injection to patients with iron overload [see Warnings and Precautions (5.3)]. Iron Sucrose Injection is not dialyzable through CA210 (Baxter) High Efficiency or Fresenius F80A High Flux dialysis membranes. Toxicities in single-dose studies in mice and rats, at intravenous iron sucrose doses up to 8 times the maximum recommended human dose based on body surface area, included sedation, hypoactivity, pale eyes, bleeding in the gastrointestinal tract and lungs, and mortality.